Last reviewed · How we verify
Firazyr
At a glance
| Generic name | Firazyr |
|---|---|
| Also known as | Icatibant acetate |
| Sponsor | Sebastian Videla |
| Target | B1 bradykinin receptor, B2 bradykinin receptor, B1 bradykinin receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Hereditary angioneurotic edema
Common side effects
- Injection site reaction
- Pyrexia
- Transaminase increased
- Dizziness
- Rash
- Nausea
- Headache
Serious adverse events
- Urticaria
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
- A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
- A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema (PHASE4)
- A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 (PHASE4)
- FIRAZYR General Drug Use-Results Survey (Japan)
- A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |